Product Recall
Definition
Product recall is a process taken by the manufacturer, importer and wholesaler to remove or withdraw a particular products from all links of distribution.
The removal or withdrawal may be due to critical quality defects discovered or serious adverse drug reactions reported which might cause health risks to users of the products.
Decision For Recall
The decision for recall shall be made when there is or may caused potential risk to the user of the products by reason of faulty production or on medical grounds:
a) Voluntarily undertaken by the manufacturers and distributors.
b) As directed by the Director of Pharmaceutical Services, Ministry of Health.
Unless the Director of Pharmaceutical Services, Ministry of Health has already specified the degree and level of a particular products recall, the degree and level will be decided by the company’s Product Recall Committee based on risks involved. The Product Recall Committee shall comprise of personnel who are responsible for the execution and coordination of recall. The persons responsible shall handle all aspects of the recalls with the appropriate degree of urgency.
No recall shall take place without first consulting/informing the Authority.
Recalls that involve specific batch will not involve any other batch/batches that currently available in the market.
Not all recalls are initiated because a product is deemed unsafe or ineffective. A recall may also be conducted to remove products from the Malaysian market with quality defects that do not affect their safety and efficacy.
Degree of Recall
The degree of recall is classified according to the severity of quality defects and adverse reactions of the products.
| Degree | Definition | Recall Notice by PRH |
| I | Products with major health risks that might cause serious injuries or death. Should be under an embargo within 24 hours | Within 24 hours of recall commencement or directive |
| II | Products with minor health risks or are substandard. Should be under an embargo within 72 hours | Within 48 hours of recall commencement or directive |
| III | Products with other reasons for recall that can cause health risks to users. Should be under an embargo within 30 days or as specified | Within 72 hours of recall commencement or directive |
Level of Recall
The level of recall depends on the nature of problem, extent of the product’s distribution and degree of hazard involved.
Level A: To all consumers (end users).
Level B: To all points of sales (e.g. Hospitals, Pharmacies, Clinics, Specialist Centres).
Level C: To all sub-distributors (wholesalers).
Public Notification
Not all recalls are announced in press releases. However, when a product that has been widely distributed or poses a serious health hazard is recalled, NPRA may do so if the agency determines it is necessary to protect consumers.
References:
1) Drug Registration Guidance Document (DRGD)
2) Guideline on Good Distribution Practice
Products as listed below have been recalled from the market.
|
No |
Product Name |
Registration Number |
Active ingredients |
Batch Number |
Reason for Recall |
Degree and Level of Recall |
Registration Holder |
Date of recall |
|
1 |
Coredin Paediatric Linctus |
MAL19880311AZ |
|
19574, 19616 |
Precautionary measure following a complaint regarding the presence of particles confirmed to have originated from sugar crystallization in the product formulation. |
Voluntary recall at the point of sub-distributor (wholesaler) |
TERAPUTICS SDN BHD |
30 January 2026 |
|
2 |
Vamlo Tablets 10mg |
MAL07010993AZ |
Amlodipine |
24030132 |
Out of Trend (OOT) result for Related Substances “Impurity D” test at 18th month timepoint of stability study. |
Voluntary recall up to the point of sales |
RANBAXY (MALAYSIA) SDN. BHD. |
13 February 2026 |
|
3 |
Doxycillin Tablet 100mg |
MAL19860580AZ |
Doxycycline Hydrochloride/ Hyclate |
2403300, 2403301, 2405293 |
Out of specification result for related substance “Impurity C” test during the stability study. |
Voluntary recall up to the point of sales |
DUOPHARMA MANUFACTURING (BANGI) SDN. BHD. |
19 February 2026 |
|
4 |
Uphamol Menstrual Tablet 500/25mg |
MAL12025061X |
|
2310222 |
Out-of-specification result was observed for the dissolution test during the stability study. |
Voluntary recall up to the point of sales |
Duopharma Marketing Sdn. Bhd. |
9 February 2026 |
|
5 |
Gastrografin Aqueous Solution |
MAL20001254ACRZ |
|
MA04LDV M1, MA04LDV M2, MA04MPS M1, MA04MPS M2 |
Precautionary measure following the detection of trace amounts of nitrosamine N-nitroso-meglumine above the acceptable intake limit in seven tested batches of the formulation without star anise oil. |
Voluntary recall up to the point of sales |
Bayer Co. (Malaysia) Sdn. Bhd. |
9 Mac 2026 |
|
6 |
Pro-Stisol Waist & Body Tonic Tablet |
MAL16100054T |
|
013/2412 T22-004 |
The batch tested by NPRA had failed physical appearance test |
Degree III recall up to the point of sales |
Pro Stisol Manufacturing |
13 Mac 2026 |
|
7 |
Vitamode Astaxanthin Plus Glutathione Capsule |
MAL15045003NC |
|
5NC10503 |
Product labelling on the blister strip found to be incorrect. |
Voluntary recall up to the point of sales |
Medispec (M) Sdn. Bhd. |
16 Mac 2026 |
|
8 |
Axcel Mometasone 0.05%w/w Nasal Spray |
MAL14025010AZ |
Mometasone Furoate |
B2509050, B2509050A, B2509064A |
Out of Specification (OOS) for microbial limit test was detected during the stability study programme. |
Voluntary recall up to all consumers level (end users) |
Kotra Pharma (M) Sdn. Bhd. |
10 April 2026 |
|
9 |
Glumet XR Tablet 500mg |
MAL13015050AZ |
Metformin Hydrochloride 500mg |
5036723 |
Detection of N-Nitrosodimethylamine (NDMA) above acceptable levels. |
Degree II recall up to the point of sales |
Pharmaniaga Manufacturing Berhad |
15 April 2026 |
|
10 |
Glumet XR Tablet 750mg |
MAL13025046AZ |
Metformin Hydrochloride 750mg |
5031724 |
Detection of N-Nitrosodimethylamine (NDMA) above acceptable levels. |
Degree II recall up to the point of sales |
Pharmaniaga Manufacturing Berhad |
15 April 2026 |
|
11 |
Glumet XR Tablet 500mg |
MAL13015050AZ |
Metformin Hydrochloride 500mg |
5028486 5032332 5032334 2034104 5034103 5034100 5036722 5036724 5036723 5037167 5036983 5036984 5038424 5039549 5040444 |
Detection of N-Nitrosodimethylamine (NDMA) above acceptable levels. |
Voluntary recall up to the point of sales |
Pharmaniaga Manufacturing Berhad |
14 May 2026 |
|
12 |
Glumet XR Tablet 750mg |
MAL13025046AZ |
Metformin Hydrochloride 750mg |
5029183 5030138 5030777 5030778 5030779 5031726 5031728 5031724 5032581 5032577 5033837 5034636 5035512 5035844 5037253 5040469 |
Detection of N-Nitrosodimethylamine (NDMA) above acceptable levels. |
Voluntary recall up to the point of sales |
Pharmaniaga Manufacturing Berhad |
14 May 2026 |
|
13 |
Apalin 250mg Injection (2ml Amp) |
MAL19984033AZ |
Amikacin Sulphate |
242837T |
The batch tested by NPRA had failed sterility test |
Degree I recall up to the point of sales |
Duopharma (M) Sdn. Bhd |
14 May 2026 |
|
14 |
Vegesamine Capsule 500mg |
MAL08111949XR |
Glucosamine HCl |
1770600A (182/AO), 1770600A (182/AO), 1770600A (182/AO), 1770600A (182/AP), 1770600A (182/AP), 1770600A (182/AP), 698300 (182/AQ), 698300 (182/AQ) |
This recall is being conducted because the product registration has expired on 7th December 2025 and exemption period for marketing purpose is coming to an end on 6th June 2026. |
Voluntary recall up to the point of sales |
21st Century Products Sdn. Bhd. |
20 May 2026 |
|
15 |
Nature's Green Ying Nin Tablets |
MAL14105008T |
Multiple active ingredients |
2505311 |
The batch tested by NPRA had failed physical appearance test. |
Degree III recall up to the point of sales |
Tong Jum Chew (M) Sdn. Bhd. |
15 June 2026 |
|
16 |
NutrinLife Man Pro Capsule |
MAL19036043NCR |
|
H09823310 |
Out of Specification result was observed for zinc content (ICP-OES). |
Voluntary recall up to the point of sales |
Biofunction Marketing Sdn. Bhd |
19 June 2026 |
|
17 |
Doxycillin Tablet 100mg |
MAL19860580AZ |
Doxycycline Hydrochloride |
2410251, 2410252, 2410253, 2410254 2503230, 2503231, 2503232 |
Out of Specification (OOS) for Related Substances (Impurity F test) was detected during batch monitoring following a previous product recall exercise. |
Voluntary recall up to the point of sales |
Duopharma Manufacturing (Bangi) Sdn. Bhd. |
25 June 2026 |
|
18 |
Decondine Syrup |
MAL19860261AZ |
|
307-24002, 307-24003, 307-24004, 307-24005, 307-24008, 307-24009, 307-24010, 307-24011, 307-24012, 307-24013 |
Precautionary measure following the out-of-specification result was observed for the assay test (Triprolidine HCL) for batch 307-22007 at the 30-month stability study time point, which is near the end of the product’s shelf life. |
Voluntary recall at the point of sub-distributor (wholesaler) |
Sunward Pharmaceutical Sdn. Bhd. |
3 July 2026 |
|
19 |
Idaman Pharma Enalapril Tablet 5mg |
MAL23116014AZ |
Enalapril Maleate |
5034698 |
Out of Specification result was observed for dissolution test at 18 month timepoint stability testing. |
Voluntary recall up to the point of sales |
Inspirapharma Sdn. Bhd. |
8 July 2026 |
|
20 |
Lanzotred soft capsules (Enzalutamide Soft capsules 40 mg) |
MAL22096035AZ |
Enzalutamide |
F10753P2 & G19850P2 |
Out of Specification result was observed for the impurity Enzalutamide Dioxoimidazolidine. |
Voluntary recall up to the point of sales |
Dr. Reddy`s Laboratories Malaysia Sdn. Bhd. |
3 August 2026 |
|
21 |
TSART 40 (Telmisartan Tablets USP 40mg) |
MAL19056110AZ |
Telmisartan |
25142819 |
Out of Specification result was observed for the product description at 9th months stability time point. |
Voluntary recall at the point of sub-distributor (wholesaler) |
Ascend Laboratories Sdn. Bhd. |
4 August 2026 |
|
Last updated 07/08/2026 |
||||||||








